IDEXX Laboratories Announces Second Quarter Results

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.

“Our innovation-driven strategy delivered robust global growth in the second quarter,” said Jay Mazelsky, President and Chief Executive Officer. "We saw exceptional momentum with IDEXX InVue Dx™ placements, exceeding expectations as veterinarians adopted this slide-free technology to streamline workflows and gain faster, more accurate clinical insights. This growth builds on the successful launch of IDEXX Cancer Dx™ in North America. Our focus on helping veterinarians gain deeper diagnostic insights to inform patient care continues to drive customer loyalty and sets a solid foundation for sustained long-term growth."

Second Quarter Results

The Company reports revenues of $1,109 million for the second quarter of 2025, an increase of 11% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 11% as reported and 10% organic, and Water revenue growth of 9% as reported and 8% organic.

Second quarter earnings per diluted share (“EPS”) were $3.63, an increase of 49% as reported and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to a prior year period discrete litigation expense accrual. Second quarter EPS included $0.03 per share benefit from currency changes and $0.10 per share in tax benefits from share-based compensation. Second quarter EPS also benefited by $0.07 per share from a discrete tax reserve release.

Second Quarter Performance Highlights

Companion Animal Group (“CAG”)

CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic, including 15% reported and 11% organic gains in International regions, and 6% reported and organic growth in the U.S., outpacing sector growth levels.

Additional U.S. companion animal practice key metrics are available in the Q2 2025 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Continued strong IDEXX commercial execution drove net customer gains and solid price realization while enabling our veterinary customers to increase diagnostic utilization, including benefits from recently launched IDEXX innovations, aiding expansion of CAG Diagnostics recurring revenues.

• IDEXX VetLab^® consumables generated 15% reported and 14% organic revenue growth, with testing utilization gains across regions, benefits from recent product launches, and 10% growth in IDEXX's global premium instrument installed base.

• Reference laboratory diagnostic and consulting services generated 6% reported and 5% organic revenue growth, including benefits from higher testing volumes and net price gains.

• Rapid assay products revenues declined 3% on a reported and organic basis, with volumes impacted from the recent launch of the Catalyst^® Pancreatic Lipase Test, which shifted some testing across modalities, offsetting net price benefits.

CAG Diagnostics capital instrument revenues expanded 66% as reported and 62% on an organic basis led by record quarterly instrument placements. Veterinary software, services and diagnostic imaging systems recurring and total revenues grew 9% on a reported and organic basis, led by continued momentum in cloud-based software attachments and installed base.

Water

Water revenues grew 9% as reported and 8% organic for the quarter, reflecting solid organic growth across major regions, with double-digit International growth.

Livestock, Poultry and Dairy (“LPD”)

LPD revenues increased 5% as reported and 3% organic for the quarter, led by commercial execution in North America and Asia Pacific.

Gross Profit and Operating Profit

Gross profits increased 12% as reported and 11% on a comparable basis. Gross margin of 62.6% increased 90 basis points as reported and 110 basis points on a comparable basis, supported by strong growth in IDEXX VetLab consumables revenue, Reference Labs productivity initiatives, and benefits from net price realization helping to offset inflationary impacts.

Operating margin was 33.6% for the quarter, higher than the prior year period by 730 basis points as reported and by 130 basis points on a comparable basis, net of ~600 basis points impact from lapping the prior year period $61.5 million discrete litigation expense accrual. Operating margin results reflect 9% operating expense decline as reported and 9% growth on a comparable basis, net of a 19% growth benefit from comparisons to the prior year period discrete litigation expense accrual. Comparable operating expense growth was driven by higher R&D spend related to advancing the Company's innovation agenda and higher sales and marketing expense aligned with commercial activities to enable new product launches and sector development.

2025 Growth and Financial Performance Outlook

The Company is updating its full year revenue growth guidance range to $4,205 million - $4,280 million, or reported growth of 7.7% - 9.7%, an increase of $90 million at midpoint. This reflects a positive adjustment of ~2% at midpoint to full year estimates for reported revenue growth, reflecting solid CAG Diagnostics recurring revenue performance, outlook for higher IDEXX inVue Dx instrument placements and revenues, and the recent weakening of the U.S. dollar aligned with the foreign currency exchange rate assumptions set forth in this earnings release. The Company is increasing its outlook for organic revenue growth to 7% - 9%, an increase of 50 basis points at midpoint, reflecting the noted operational performance benefits.

The Company updated its full year reported operating margin outlook of 31.3% - 31.6%, bringing the projected full year comparable operating profit margin expansion to 50 - 80 basis points. This outlook incorporates planned commercial expansions in select international regions in the second half, while advancing a modest commercial expansion in the U.S., to manage our growing portfolio of diagnostic solutions.

The Company updated its EPS outlook range to $12.40 - $12.76, incorporating a $0.40 increase at midpoint versus prior guidance, reflecting $0.11 benefit from operational performance, $0.09 from higher share-based compensation benefits, $0.02 net unfavorable adjustment to effective tax rate excluding share-based compensation benefits and including the release of a discrete tax reserve, and $0.22 in favorable adjustments to foreign exchange estimates. The updated EPS growth outlook is 16% - 20% as reported and 9% - 13% growth on a comparable basis.

The following table provides the Company's updated outlook for annual key financial metrics in 2025 with a comparison to the prior outlook:

Amounts in millions except per share data and percentages
2025 Growth and Financial Performance Outlook
		Updated				Prior
Revenue		$4,205	-	$4,280		$4,095	-	$4,210
Reported growth		7.7%	-	9.7%		5.0%	-	8.0%
Organic growth		7.0%	-	9.0%		6.0%	-	9.0%
CAG Diagnostics Recurring Revenue Growth
Reported growth		6.5%	-	8.7%		4.0%	-	7.0%
Organic growth		5.8%	-	8.0%		5.0%	-	8.0%
Operating Margin		31.3%	-	31.6%		31.1%	-	31.6%
Operating margin expansion		240 bps	-	270 bps		210 bps	-	260 bps
Comparable margin expansion		50 bps	-	80 bps		30 bps	-	80 bps
EPS		$12.40	-	$12.76		$11.93	-	$12.43
Reported growth		16%	-	20%		12%	-	17%
Comparable growth		9%	-	13%		8%	-	12%
Other Key Metrics
Net interest expense		~ $42				~ $42
Share-based compensation tax benefit		~ $15				~ $8
Share-based compensation tax rate benefit		~ 1.2%				~ 1%
Effective tax rate		~ 21.0%				~ 21.5%
Share-based compensation EPS impact		~ $0.19				~ $0.10
Reduction in average shares outstanding		2%	-	3%		2%	-	3%
Operating Cash Flow (% of Net Income)		95%	-	105%		95%	-	105%
Free Cash Flow (% of Net Income)		80%	-	85%		80%	-	85%
Capital Expenditures		~ $160				~ $160

The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2025.

Estimated Foreign Currency Exchange Rate Impacts		2025
Revenue growth rate impact		~0.7%
CAG Diagnostics recurring revenue growth rate impact		~0.7%
Operating margin growth impact		~ 10 bps
EPS impact		~ $0.12
EPS growth impact		~ 1%
Go-Forward Foreign Currency Exchange Rate Assumptions		2025
In U.S. dollars
euro		$1.15
British pound		$1.34
Canadian dollar		$0.72
Australian dollar		$0.64
Relative to the U.S. dollar
Japanese yen		¥149
Chinese renminbi		¥7.26
Brazilian real		R$5.55

Conference Call and Webcast Information

IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its second quarter 2025 results and management’s outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-289-0462 or 1-323-794-2442 and reference passcode 595638.

2025 Investor Day

IDEXX Laboratories, Inc. will host its 2025 Investor Day on Thursday, August 14, 2025 from 8:00 am to approximately 12:00 pm (EDT). A live webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately one hour following the event at www.idexx.com/investors. For additional information, contact investorrelations@idexx.com.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500^® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

Note Regarding Forward-Looking Statements

This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included above under "2025 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; projected impact of tariffs; trends and other factors impacting the pet healthcare industry; net price realization improvement; IDEXX inVue Dx^TM analyzer placements and revenues; timing of the international roll-out of the IDEXX Cancer Dx^TM testing panel; and future product launches and menu expansions. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted second quarter 2025 results as follows: increased gross profit growth by 0.9%, decreased gross margin growth by 20 basis points, increased operating expense growth by 0.8%, increased operating profit growth by 1.1%, decreased operating profit margin growth by 10 basis points, and increased EPS growth by 1.2%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three and six months ended June 30, 2025 and refer to the 2025 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2025 projections and estimates.

Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percent change in revenue, as compared to the same period for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and six months ended June 30, 2025. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2025 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2025 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full year 2025 revenue growth and no impact on CAG Diagnostics recurring revenue growth.

Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

		Three Months Ended								Year-over-Year		Six Months Ended								Year-over-Year
Dollar amounts in thousands		June 30,				June 30,				Change		June 30,				June 30,				Change
		2025				2024						2025				2024
Gross Profit (as reported)		$	694,732			$	619,159			12%		$	1,318,111			$	1,212,229			9%
Gross margin			62.6	%			61.7	%		90 bps			62.5	%			61.6	%		90 bps
Less: comparability adjustments
Change from currency			5,765				—						(1,142	)			—
Comparable gross profit growth		$	688,967			$	619,159			11%		$	1,319,253			$	1,212,229			9%
Comparable gross margin and gross margin gain (or growth)			62.8	%			61.7	%		110 bps			62.6	%			61.6	%		100 bps
Operating expenses (as reported)		$	321,686			$	355,358			(9)%		$	628,531			$	649,470			(3)%
Less: comparability adjustments
Change from currency			2,744				—						(75	)			—
Now-concluded litigation matter			—				61,500						(8,600	)			61,500
Comparable operating expense growth		$	318,942			$	293,858			9%		$	637,206			$	587,970			8%
Income from operations (as reported)		$	373,046			$	263,801			41%		$	689,580			$	562,759			23%
Operating margin			33.6	%			26.3	%		730 bps			32.7	%			28.6	%		410 bps
Less: comparability adjustments
Change from currency			3,021				—						(1,067	)			—
Now-concluded litigation matter			—				(61,500	)					8,600				(61,500	)
Comparable operating profit growth		$	370,025			$	325,301			14%		$	682,047			$	624,259			9%
Comparable operating margin and operating margin gain (or growth)			33.7	%			32.4	%		130 bps			32.4	%			31.7	%		60 bps
Amounts presented may not recalculate due to rounding.

Projected 2025 comparable operating margin expansion outlined in the 2025 Growth and Financial Performance Outlook section of this earnings release reflects adjustments to projected 2025 operating margin expansion for: (i) an immaterial impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (ii) positive impact of the approximately $9 million discrete litigation expense accrual adjustment in the first quarter of 2025; and (iii) adjustment to full year 2024 reported operating margin expansion for the negative impact of the $61.5 million discrete litigation expense accrual adjustment in the second quarter of 2024.

These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2025 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

		Three Months Ended							Year-over-Year		Six Months Ended							Year-over-Year
		June 30,			June 30,				Growth		June 30,				June 30,			Growth
		2025			2024						2025				2024
Earnings per share (diluted)		$	3.63		$	2.44			49%		$	6.59			$	5.24		26%
Less: comparability adjustments
Share-based compensation activity			0.10			—						0.11				0.10
Now-concluded litigation matter			—			(0.56	)					0.08				(0.56	)
Change from currency			0.03			—						(0.01	)			—
Comparable EPS growth		$	3.50		$	3.00			17%		$	6.41			$	5.70		12%
Amounts presented may not recalculate due to rounding.

Projected 2025 comparable EPS growth outlined in the 2025 Growth and Financial Performance Outlook section of this earnings release reflects adjustments to projected full year 2025 reported EPS for: (i) estimated positive share-based compensation activity of ~$0.19; and (ii) estimated positive year-over-year foreign currency exchange rate change impact of ~$0.12 at noted exchange rates; (iii) adjustment to projected full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense accrual adjustment in the first quarter of 2025; (iv) adjustment to full year 2024 reported EPS for a negative $0.56 impact from the discrete litigation expense accrual adjustment in the second quarter of 2024; and (v) positive impact of share-based compensation activity of $0.24.

These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2025 reported EPS growth) to comparable EPS growth for the Company.

Segment and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in evaluating the performance of each reportable segment.

The reconciliation of this non-GAAP financial measure is as follows for the three and six months ended June 30, 2025 and 2024:

Amounts in thousands		For the Three Months Ended June 30,
		2025												2024
		Income from Operations				Impact from Foreign Currency				Segment and Other Income from Operations				Income from Operations			Impact from Foreign Currency				Segment and Other Income from Operations
CAG		$	347,983			$	494			$	348,477			$	240,687		$	863			$	241,550
Water			24,606				36				24,642				20,439			65				20,504
LPD			(543	)			38				(505	)			1,426			73				1,499
Other			1,000				(568	)			432				1,249			(1,001	)			248
Total		$	373,046			$	—			$	373,046			$	263,801		$	—			$	263,801

Amounts in thousands		For the Six Months Ended June 30,
		2025												2024
		Income from Operations				Impact from Foreign Currency				Segment and Other Income from Operations				Income from Operations			Impact from Foreign Currency				Segment and Other Income from Operations
CAG		$	642,554			$	1,078			$	643,632			$	519,573		$	1,673			$	521,246
Water			45,380				79				45,459				39,811			123				39,934
LPD			(462	)			82				(380	)			2,227			138				2,365
Other			2,108				(1,239	)			869				1,148			(1,934	)			(786	)
Total		$	689,580			$	—			$	689,580			$	562,759		$	—			$	562,759

Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three months and six months ended June 30, 2025 and 2024. To estimate projected 2025 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $160 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended June 30, 2025, we have deducted purchases of property and equipment of approximately $121 million from net cash provided from operating activities of approximately $906 million, divided by net income of approximately $986 million.

Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Notes and Definitions

Discrete litigation expense accrual - During the second quarter of 2024, the Company increased its previously established $27.5 million accrual related to a now-concluded litigation matter by $61.5 million. During the first quarter of 2025, the Company reduced this previously established $89.0 million accrual by approximately $9 million, resulting in a total accrual for this now-concluded litigation matter of approximately $80 million as of March 31, 2025, which represented our best estimate of the amount of the loss.

Now-concluded litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court on the same date, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Discrete tax reserve release - During the second quarter of 2025, the Company released a previously-established reserve following the resolution of certain international tax audits.

IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)
				Three Months Ended						Six Months Ended
				June 30,			June 30,			June 30,			June 30,
				2025			2024			2025			2024
Revenue:		Revenue		$1,109,457			$1,003,578			$2,107,884			$1,967,673
Expenses and Income:		Cost of revenue		414,725			384,419			789,773			755,444
		Gross profit		694,732			619,159			1,318,111			1,212,229
		Sales and marketing		161,107			142,665			317,330			292,118
		General and administrative		98,681			157,243			190,242			249,267
		Research and development		61,898			55,450			120,959			108,085
		Total operating expense		321,686			355,358			628,531			649,470
		Income from operations		373,046			263,801			689,580			562,759
		Interest expense, net		(10,694	)		(4,745	)		(17,144	)		(8,224	)
		Income before provision for income taxes		362,352			259,056			672,436			554,535
		Provision for income taxes		68,363			55,758			135,770			115,658
Net Income:		Net income attributable to stockholders		$293,989			$203,298			$536,666			$438,877
		Earnings per share: Basic		$3.66			$2.46			$6.64			$5.30
		Earnings per share: Diluted		$3.63			$2.44			$6.59			$5.24
		Shares outstanding: Basic		80,413			82,630			80,864			82,863
		Shares outstanding: Diluted		80,994			83,393			81,465			83,684

IDEXX Laboratories, Inc. and Subsidiaries
Selected Operating Information (Unaudited)
				Three Months Ended				Six Months Ended
				June 30,		June 30,		June 30,		June 30,
				2025		2024		2025		2024
Operating Ratios		Gross profit		62.6%		61.7%		62.5%		61.6%
(as a percentage of revenue):		Sales, marketing, general and administrative expense		23.4%		29.9%		24.1%		27.5%
		Research and development expense		5.6%		5.5%		5.7%		5.5%
		Income from operations1		33.6%		26.3%		32.7%		28.6%
1Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries
Segment and Other Information
Amounts in thousands (Unaudited)
				Three Months Ended
				June 30, 2025		Percent of Revenue		June 30, 2024		Percent of Revenue
Revenue:		CAG		$1,022,443				$922,298
		Water		51,001				46,726
		LPD		31,762				30,306
		Other		4,251				4,248
		Total		$1,109,457				$1,003,578
Gross Profit:		CAG		$642,102		62.8 %		$569,071		61.7 %
		Water		35,511		69.6 %		32,074		68.6 %
		LPD		14,929		47.0 %		15,558		51.3 %
		Other		2,190		51.5 %		2,456		57.8 %
		Total		$694,732		62.6 %		$619,159		61.7 %
Income from Operations:		CAG		$348,477		34.1 %		$241,550		26.2 %
		Water		24,642		48.3 %		20,504		43.9 %
		LPD		(505)		(1.6) %		1,499		4.9 %
		Other		432		10.2 %		248		5.8 %
		Total		$373,046		33.6 %		$263,801		26.3 %

				Six Months Ended
				June 30, 2025		Percent of Revenue		June 30, 2024		Percent of Revenue
Revenue:		CAG		$1,942,279				$1,811,583
		Water		96,322				89,797
		LPD		60,358				58,511
		Other		8,925				7,782
		Total		$2,107,884				$1,967,673
Gross Profit:		CAG		$1,216,925		62.7 %		$1,115,307		61.6 %
		Water		67,584		70.2 %		62,571		69.7 %
		LPD		29,294		48.5 %		30,792		52.6 %
		Other		4,308		48.3 %		3,559		45.7 %
		Total		$1,318,111		62.5 %		$1,212,229		61.6 %
Income from Operations:		CAG		$643,632		33.1 %		$521,246		28.8 %
		Water		45,459		47.2 %		39,934		44.5 %
		LPD		(380)		(0.6) %		2,365		4.0 %
		Other		869		9.7 %		(786)		(10.1) %
		Total		$689,580		32.7 %		$562,759		28.6 %

IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
Amounts in thousands (Unaudited)
		Three Months Ended
		June 30, 2025		June 30, 2024		Dollar Change		Reported Revenue Growth1		Percentage Change from Currency		Percentage Change from Acquisitions		Organic Revenue Growth1
Net Revenue
CAG		$1,022,443		$922,298		$100,145		10.9%		1.2 %		—		9.7 %
United States		684,497		628,684		55,813		8.9%		—		—		8.9 %
International		337,946		293,614		44,332		15.1%		3.8 %		—		11.3 %
Water		51,001		46,726		4,275		9.1%		0.8 %		—		8.4 %
United States		26,090		24,461		1,629		6.7%		—		—		6.7 %
International		24,911		22,265		2,646		11.9%		1.7 %		—		10.2 %
LPD		31,762		30,306		1,456		4.8%		2.2 %		—		2.6 %
United States		5,767		5,115		652		12.8%		—		—		12.8 %
International		25,995		25,191		804		3.2%		2.6 %		—		0.6 %
Other		4,251		4,248		3		0.1%		—		—		0.1 %
Total Company		$1,109,457		$1,003,578		$105,879		10.6%		1.2 %		—		9.3 %
United States		717,869		660,146		57,723		8.7%		—		—		8.7 %
International		391,588		343,432		48,156		14.0%		3.6 %		—		10.5 %

		Three Months Ended
		June 30, 2025		June 30, 2024		Dollar Change		Reported Revenue Growth1		Percentage Change from Currency		Percentage Change from Acquisitions		Organic Revenue Growth1
Net CAG Revenue
CAG Diagnostics recurring revenue:		$877,995		$808,454		$69,541		8.6 %		1.2 %		—		7.4 %
IDEXX VetLab consumables		375,112		325,348		49,764		15.3 %		1.7 %		—		13.6 %
Rapid assay products		100,240		103,290		(3,050)		(3.0) %		0.4 %		—		(3.3) %
Reference laboratory diagnostic and consulting services		367,694		347,373		20,321		5.9 %		1.1 %		—		4.8 %
CAG Diagnostics services and accessories		34,949		32,443		2,506		7.7 %		1.7 %		—		6.0 %
CAG Diagnostics capital – instruments		58,600		35,292		23,308		66.0 %		3.5 %		—		62.5 %
Veterinary software, services and diagnostic imaging systems:		85,848		78,552		7,296		9.3 %		0.1 %		—		9.2 %
Recurring revenue		68,954		63,117		5,837		9.2 %		0.2 %		—		9.1 %
Systems and hardware		16,894		15,435		1,459		9.5 %		—		—		9.4 %
Net CAG revenue		$1,022,443		$922,298		$100,145		10.9 %		1.2 %		—		9.7 %

		Three Months Ended
		June 30, 2025		June 30, 2024		Dollar Change		Reported Revenue Growth1		Percentage Change from Currency		Percentage Change from Acquisitions		Organic Revenue Growth1
CAG Diagnostics recurring revenue:		$877,995		$808,454		$69,541		8.6 %		1.2 %		—		7.4 %
United States		575,009		544,466		30,543		5.6 %		—		—		5.6 %
International		302,986		263,988		38,998		14.8 %		3.9 %		—		10.9 %
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
Amounts in thousands (Unaudited)
		Six Months Ended
		June 30, 2025		June 30, 2024		Dollar Change		Reported Revenue Growth1		Percentage Change from Currency		Percentage Change from Acquisitions		Organic Revenue Growth1
Net Revenue
CAG		$1,942,279		$1,811,583		$130,696		7.2%		—		0.1 %		7.1 %
United States		1,308,386		1,230,879		77,507		6.3%		—		0.1 %		6.2 %
International		633,893		580,704		53,189		9.2%		0.1 %		—		9.1 %
Water		96,322		89,797		6,525		7.3%		(0.6) %		—		7.9 %
United States		49,593		46,660		2,933		6.3%		—		—		6.3 %
International		46,729		43,137		3,592		8.3%		(1.3) %		—		9.6 %
LPD		60,358		58,511		1,847		3.2%		(0.2) %		—		3.4 %
United States		11,555		10,279		1,276		12.4%		—		—		12.4 %
International		48,803		48,232		571		1.2%		(0.2) %		—		1.4 %
Other		8,925		7,782		1,143		14.7%		—		—		14.7 %
Total Company		$2,107,884		$1,967,673		$140,211		7.1%		—		0.1 %		7.1 %
United States		1,372,730		1,291,155		81,575		6.3%		—		0.1 %		6.2 %
International		735,154		676,518		58,636		8.7%		—		—		8.7 %

		Six Months Ended
		June 30, 2025		June 30, 2024		Dollar Change		Reported Revenue Growth1		Percentage Change from Currency		Percentage Change from Acquisitions		Organic Revenue Growth1
Net CAG Revenue
CAG Diagnostics recurring revenue:		$1,684,262		$1,588,598		$95,664		6.0 %		—		—		6.0 %
IDEXX VetLab consumables		719,891		642,277		77,614		12.1 %		—		—		12.1 %
Rapid assay products		184,274		189,605		(5,331)		(2.8) %		(0.1) %		—		(2.7) %
Reference laboratory diagnostic and consulting services		712,100		691,711		20,389		2.9 %		0.1 %		—		2.9 %
CAG Diagnostics services and accessories		67,997		65,005		2,992		4.6 %		—		—		4.6 %
CAG Diagnostics capital – instruments		90,594		69,384		21,210		30.6 %		0.4 %		—		30.1 %
Veterinary software, services and diagnostic imaging systems:		167,423		153,601		13,822		9.0 %		(0.2) %		0.9 %		8.3 %
Recurring revenue		134,747		122,817		11,930		9.7 %		(0.2) %		0.9 %		9.0 %
Systems and hardware		32,676		30,784		1,892		6.1 %		(0.2) %		0.8 %		5.6 %
Net CAG revenue		$1,942,279		$1,811,583		$130,696		7.2 %		—		0.1 %		7.1 %

		Six Months Ended
		June 30, 2025		June 30, 2024		Dollar Change		Reported Revenue Growth1		Percentage Change from Currency		Percentage Change from Acquisitions		Organic Revenue Growth1
CAG Diagnostics recurring revenue:		$1,684,262		$1,588,598		$95,664		6.0 %		—		—		6.0 %
United States		1,111,986		1,067,507		44,479		4.2 %		—		—		4.2 %
International		572,276		521,091		51,185		9.8 %		0.1 %		—		9.7 %
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet
Amounts in thousands (Unaudited)
				June 30, 2025		December 31, 2024
Assets:		Current Assets:
		Cash and cash equivalents		$164,594		$288,266
		Accounts receivable, net		560,563		473,575
		Inventories		392,584		381,877
		Other current assets		244,616		256,179
		Total current assets		1,362,357		1,399,897
		Property and equipment, net		739,677		713,123
		Other long-term assets, net		1,228,760		1,180,423
		Total assets		$3,330,794		$3,293,443
Liabilities and Stockholders'
Equity:		Current Liabilities:
		Accounts payable		$116,585		$114,211
		Accrued liabilities		416,977		502,119
		Line of credit		579,000		250,000
		Current portion of long-term debt		74,994		167,787
		Deferred revenue		36,324		33,799
		Total current liabilities		1,223,880		1,067,916
		Long-term debt, net of current portion		449,812		449,786
		Other long-term liabilities, net		198,275		180,428
		Total long-term liabilities		648,087		630,214
		Total stockholders' equity		1,458,827		1,595,313
		Total liabilities and stockholders' equity		$3,330,794		$3,293,443

IDEXX Laboratories, Inc. and Subsidiaries
Selected Balance Sheet Information (Unaudited)
				June 30, 2025		March 31, 2025		December 31, 2024		September 30, 2024		June 30, 2024
Selected Balance Sheet Information:		Days sales outstanding1		44.7		45.7		47.1		48.9		47.3
		Inventory turns2		1.5		1.3		1.3		1.3		1.4
1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.
2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)
				Six Months Ended
				June 30, 2025			June 30, 2024
Operating:		Cash Flows from Operating Activities:
		Net income		$536,666			$438,877
		Non-cash adjustments to net income		111,582			75,155
		Changes in assets and liabilities		(224,543	)		(67,135	)
		Net cash provided by operating activities		423,705			446,897
Investing:		Cash Flows from Investing Activities:
		Purchases of property and equipment		(64,128	)		(63,578	)
		Acquisition of a business		—			(77,000	)
		Proceeds from net investment hedges		890			727
		Net cash used by investing activities		(63,238	)		(139,851	)
Financing:		Cash Flows from Financing Activities:
		Borrowings under credit facility, net		329,000			—
		Payments of senior notes		(103,386	)		—
		Repurchases of common stock		(738,995	)		(370,285	)
		Proceeds from exercises of stock options and employee stock purchase plans		24,523			26,241
		Shares withheld for statutory tax withholding payments on restricted stock		(7,094	)		(10,268	)
		Net cash used by financing activities		(495,952	)		(354,312	)
		Net effect of changes in exchange rates on cash		11,813			(5,076	)
		Net decrease in cash and cash equivalents		(123,672	)		(52,342	)
		Cash and cash equivalents, beginning of period		288,266			453,932
		Cash and cash equivalents, end of period		$164,594			$401,590

IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)
				Three Months Ended						Six Months Ended
				June 30, 2025			June 30, 2024			June 30, 2025			June 30, 2024
Free Cash Flow:		Net cash provided by operating activities		$185,743			$248,312			$423,705			$446,897
		Investing cash flows attributable to purchases of property and equipment		(34,102	)		(33,305	)		(64,128	)		(63,578	)
		Free cash flow1		$151,641			$215,007			$359,577			$383,319
1See Statements Regarding Non-GAAP Financial Measures, above.

IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data (Unaudited)
		Three Months Ended				Six Months Ended
		June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
Shares repurchased in the open market		713		415		1,644		718
Shares acquired through employee surrender for statutory tax withholding		2		—		16		18
Total shares repurchased		715		415		1,660		736
Cost of shares repurchased in the open market		$327,530		$208,169		$736,745		$375,271
Cost of shares for employee surrenders		970		79		7,094		10,268
Total cost of shares		$328,500		$208,248		$743,839		$385,539
Average cost per share – open market repurchases		$458.96		$501.44		$448.02		$522.32
Average cost per share – employee surrenders		$513.46		$496.95		$452.84		$560.01
Average cost per share – total		$459.10		$501.44		$448.07		$523.26

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250801722638/en/